
    
      After signing informed consent, subjects entered into the trial will be followed for up to 8
      weeks which includes: up to 4 weeks screening, entry criteria assessments on Day 0 and
      single-dose IV infusion on Day 1, and 4 weeks of follow-up.
    
  